{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:01:26Z","timestamp":1787763686297,"version":"build-2784847793"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T00:00:00Z","timestamp":1610928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005847","name":"Health and Medical Research Fund","doi-asserted-by":"publisher","award":["04151266"],"award-info":[{"award-number":["04151266"]}],"id":[{"id":"10.13039\/501100005847","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005847","name":"Health and Medical Research Fund","doi-asserted-by":"publisher","award":["05162326"],"award-info":[{"award-number":["05162326"]}],"id":[{"id":"10.13039\/501100005847","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","award":["HKU5\/CRF\/13G"],"award-info":[{"award-number":["HKU5\/CRF\/13G"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","award":["RGC17122915"],"award-info":[{"award-number":["RGC17122915"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","award":["T12-703\/19-R"],"award-info":[{"award-number":["T12-703\/19-R"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","award":["TRS-T11-706\/18-N"],"award-info":[{"award-number":["TRS-T11-706\/18-N"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003803","name":"University of Hong Kong","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003803","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncolytics"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.omto.2021.01.010","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T18:53:59Z","timestamp":1611255239000},"page":"373-386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Eliminating mesothelioma by AAV-vectored, PD1-based vaccination in the tumor microenvironment"],"prefix":"10.1016","volume":"20","author":[{"given":"Zhiwu","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Sum","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Wing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwan","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4511-2888","authenticated-orcid":false,"given":"Zhiwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omto.2021.01.010_bib1","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","article-title":"Breakthrough of the year 2013. Cancer immunotherapy","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.omto.2021.01.010_bib2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.omto.2021.01.010_bib3","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omto.2021.01.010_bib4","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omto.2021.01.010_bib5","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.omto.2021.01.010_bib6","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2021.01.010_bib7","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","article-title":"Clonal replacement of tumor-specific T\u00a0cells following PD-1 blockade","volume":"25","author":"Yost","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.omto.2021.01.010_bib8","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrd4591","article-title":"Combination cancer immunotherapy and new immunomodulatory targets","volume":"14","author":"Mahoney","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omto.2021.01.010_bib9","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omto.2021.01.010_bib10","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1158\/1078-0432.CCR-12-0781","article-title":"Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects","volume":"19","author":"Fransen","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2021.01.010_bib11","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2326-6066.CIR-13-0067","article-title":"Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer","volume":"2","author":"Sandin","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omto.2021.01.010_bib12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4049\/jimmunol.1601145","article-title":"Intratumoral Delivery of Immunotherapy-Act Locally, Think Globally","volume":"198","author":"Aznar","year":"2017","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omto.2021.01.010_bib13","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1128\/JVI.00254-08","article-title":"In\u00a0vitro and in\u00a0vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses","volume":"82","author":"Grimm","year":"2008","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omto.2021.01.010_bib14","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omto.2021.01.010_bib15","doi-asserted-by":"crossref","first-page":"6010","DOI":"10.1158\/0008-5472.CAN-14-0473","article-title":"Vaccine-elicited CD8+ T\u00a0cells cure mesothelioma by overcoming tumor-induced immunosuppressive environment","volume":"74","author":"Tan","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2021.01.010_bib16","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1172\/JCI64704","article-title":"PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8+ T\u00a0cells in mice","volume":"123","author":"Zhou","year":"2013","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omto.2021.01.010_bib17","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.omto.2020.01.009","article-title":"Antimesothelioma Immunotherapy by CTLA-4 Blockade Depends on Active PD1-Based TWIST1 Vaccination","volume":"16","author":"Tan","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omto.2021.01.010_bib18","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1038\/s41467-019-10594-2","article-title":"Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade","volume":"10","author":"D\u2019Alise","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omto.2021.01.010_bib19","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S1470-2045(18)30100-1","article-title":"Novel therapies for malignant pleural mesothelioma","volume":"19","author":"Scherpereel","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omto.2021.01.010_bib20","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/imr.12657","article-title":"The function and dysfunction of memory CD8+ T\u00a0cells in tumor immunity","volume":"283","author":"Reading","year":"2018","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.omto.2021.01.010_bib21","doi-asserted-by":"crossref","first-page":"6020","DOI":"10.1128\/jvi.71.8.6020-6027.1997","article-title":"Infection of primary cells by adeno-associated virus type 2 results in a modulation of cell cycle-regulating proteins","volume":"71","author":"Hermanns","year":"1997","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omto.2021.01.010_bib22","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/35091082","article-title":"Virus-mediated killing of cells that lack p53 activity","volume":"412","author":"Raj","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.omto.2021.01.010_bib23","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s11481-016-9654-0","article-title":"Brain Invasion by CD4(+) T Cells Infected with a Transmitted\/Founder HIV-1BJZS7 During Acute Stage in Humanized Mice","volume":"11","author":"Wu","year":"2016","journal-title":"J.\u00a0Neuroimmune Pharmacol."},{"key":"10.1016\/j.omto.2021.01.010_bib24","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1016\/j.ymthe.2019.09.016","article-title":"Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses","volume":"27","author":"Ballesteros-Briones","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2021.01.010_bib25","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3389\/fonc.2019.00052","article-title":"Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors","volume":"9","author":"Reul","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omto.2021.01.010_bib26","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/mt.2012.260","article-title":"Oral vaccination with adeno-associated virus vectors expressing the Neu oncogene inhibits the growth of murine breast cancer","volume":"21","author":"Steel","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2021.01.010_bib27","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.omto.2019.10.001","article-title":"An Engineered AAV6-Based Vaccine Induces High Cytolytic Anti-Tumor Activity by Directly Targeting DCs and Improves Ag Presentation","volume":"15","author":"Krotova","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omto.2021.01.010_bib28","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1128\/JVI.76.9.4580-4590.2002","article-title":"Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors","volume":"76","author":"Zaiss","year":"2002","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omto.2021.01.010_bib29","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/CJI.0b013e318210ed0e","article-title":"Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1","volume":"34","author":"Song","year":"2011","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.omto.2021.01.010_bib30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/mt.2010.250","article-title":"The complex and evolving story of T\u00a0cell activation to AAV vector-encoded transgene products","volume":"19","author":"Mays","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2021.01.010_bib31","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.4049\/jimmunol.173.8.4919","article-title":"Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine","volume":"173","author":"He","year":"2004","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omto.2021.01.010_bib32","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/mt.2012.252","article-title":"Adenovirus expressing both thymidine kinase and soluble PD1 enhances antitumor immunity by strengthening CD8 T-cell response","volume":"21","author":"Shin","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2021.01.010_bib33","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","article-title":"Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition","volume":"44","author":"Salmon","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.omto.2021.01.010_bib34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2021.01.010_bib35","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/mt.2014.14","article-title":"Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy","volume":"22","author":"Sallach","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2021.01.010_bib36","doi-asserted-by":"crossref","first-page":"7361","DOI":"10.1128\/jvi.71.10.7361-7371.1997","article-title":"Encapsidation of adeno-associated virus type 2 Rep proteins in wild-type and recombinant progeny virions: Rep-mediated growth inhibition of primary human cells","volume":"71","author":"Kube","year":"1997","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omto.2021.01.010_bib37","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41422-020-0337-2","article-title":"The future of cancer immunotherapy: microenvironment-targeting combinations","volume":"30","author":"Murciano-Goroff","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.omto.2021.01.010_bib38","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature16465","article-title":"An essential receptor for adeno-associated virus infection","volume":"530","author":"Pillay","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.omto.2021.01.010_bib39","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1158\/0008-5472.CAN-16-1638","article-title":"Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy","volume":"77","author":"Bartee","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2021.01.010_bib40","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41467-020-15229-5","article-title":"An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T\u00a0cell responses","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omto.2021.01.010_bib41","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/mt.2014.160","article-title":"CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy","volume":"22","author":"Engeland","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2021.01.010_bib42","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.omto.2021.01.010_bib43","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2021.01.010_bib44","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.omtm.2019.04.004","article-title":"Threshold for Pre-existing Antibody Levels Limiting Transduction Efficiency of Systemic rAAV9 Gene Delivery: Relevance for Translation","volume":"13","author":"Meadows","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omto.2021.01.010_bib45","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.omto.2021.01.010_bib46","doi-asserted-by":"crossref","first-page":"32426","DOI":"10.18632\/oncotarget.5856","article-title":"Antigen spreading-induced CD8+T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells","volume":"6","author":"Yu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.omto.2021.01.010_bib47","doi-asserted-by":"crossref","first-page":"e1518672","DOI":"10.1080\/2162402X.2018.1518672","article-title":"Virotherapy-recruited PMN-MDSC infiltration of mesothelioma blocks antitumor CTL by IL-10-mediated dendritic cell suppression","volume":"8","author":"Tan","year":"2018","journal-title":"OncoImmunology"}],"container-title":["Molecular Therapy Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770521000115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770521000115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T12:38:48Z","timestamp":1784723928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2372770521000115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":47,"alternative-id":["S2372770521000115"],"URL":"https:\/\/doi.org\/10.1016\/j.omto.2021.01.010","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eliminating mesothelioma by AAV-vectored, PD1-based vaccination in the tumor microenvironment","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncolytics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omto.2021.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s).","name":"copyright","label":"Copyright"}]}}